Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 12/20 | 0.46 |
| ▸ | MMP13 | P45452 | 3/20 | 0.46 |
| ▸ | MMP2 | P08253 | 13/20 | 0.44 |
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 9/20 | 0.43 |
| ▸ | MMP3 | P08254 | 9/20 | 0.43 |
| ▸ | MMP8 | P22894 | 5/20 | 0.43 |
| ▸ | MMP7 | P09237 | 2/20 | 0.43 |
| ▸ | FCER2 | P06734 | 1/20 | 0.43 |
| ▸ | MMP14 | P50281 | 3/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7373924 | 0.86 | MMP1 (0.45) | MMP1MMP13MMP2MMP12MMP9 | |
| SCHEMBL8189738 | 0.85 | MMP1 (0.47) | MMP1MMP13MMP2MMP12MMP9 | |
| SCHEMBL7600843 | 0.83 | MMP1 (0.48) | MMP1MMP13MMP2MMP12MMP9 | |
| SCHEMBL7595847 | 0.83 | MMP1 (0.44) | MMP1MMP13MMP2MMP12MMP9 | |
| SCHEMBL7372625 | 0.80 | MMP2 (0.51) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL7597125 | 0.79 | MMP1 (0.41) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL7596890 | 0.79 | MMP1 (0.52) | MMP1MMP13MMP2MMP12MMP9 | |
| SCHEMBL7595499 | 0.78 | MMP1 (0.47) | MMP1MMP13MMP2MMP12MMP9 | |
| SCHEMBL8197037 | 0.77 | MMP3 (0.47) | MMP1MMP13MMP2MMP12MMP9 | |
| SCHEMBL8189622 | 0.77 | MMP3 (0.47) | MMP1MMP13MMP2MMP12MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0905126-B1 | Metalloproteinase inhibitors | BRITISH BIOTECH PHARM (GB) | 2002-12-04 | — | — | EP | claimed |
| EP-1131634-A2 | DETERMINING THE MECHANISM OF BETA-AMYLOID PEPTIDE GENERATION | Elan Pharmaceuticals, Inc. (US) | 2001-09-12 | — | — | EP | claimed |
| WO-2000019210-A2 | DETERMINING THE MECHANISM OF BETA-AMYLOID PEPTIDE GENERATION | ELAN PHARMACEUTICALS, INC. (US) | 2000-04-06 | — | — | WO | claimed |
| EP-0905126-A1 | Metalloproteinase inhibitors | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-03-31 | — | — | EP | claimed |
| EP-0905126-B1 | Metalloproteinase inhibitors | BRITISH BIOTECH PHARM (GB) | 2002-12-04 | — | — | EP | disclosed |
| US-6017889-A | Metalloproteinase inhibitors | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-01-25 | — | — | US | disclosed |
| EP-0905126-A1 | Metalloproteinase inhibitors | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-03-31 | — | — | EP | disclosed |
| EP-0740655-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1996-11-06 | — | — | EP | disclosed |
| WO-1995019961-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-07-27 | — | — | WO | disclosed |